Adult vaccination

References

• WhitneyCG, ZhouF, SingletonJ, SchuchatA, Centers for Disease Control and Prevention (CDC). Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep2014; 63:352 - 5; PMID: 24759657
   PubMed Web of Science ®Google Scholar
• The 2009 Ageing Report: economic and budgetary projections for the EU-27 Member States (2008-2060) Luxembourg: Joint Report prepared by the European Commission (DG ECFIN) and the Economic Policy Committee (AWG).. 2009
   Google Scholar
• BureauUC. . Population by Age and Sex for the United States: 1900 to 2000. PartACensus 2000 Special Reports, Series CENSR-4: US Administration on Aging. , 2002
   Google Scholar
• US Census Bureau PD. Projections of the Population by Age and Sex for the United States: 2010 to 2050. US Census Bureau, Population Division, 2008.
   Google Scholar
• FitzwaterSP, ChandranA, SantoshamM, JohnsonHL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J2012; 31:501 - 8; http://dx.doi.org/10.1097/INF.0b013e31824de9f6; PMID: 22327872
   PubMed Web of Science ®Google Scholar
• SteensA, BergsakerMA, AabergeIS, RønningK, VestrheimDF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine2013; 31:6232 - 8; http://dx.doi.org/10.1016/j.vaccine.2013.10.032; PMID: 24176490
   PubMed Web of Science ®Google Scholar
• KyawMH, RoseCEJr., FryAM, SingletonJA, MooreZ, ZellER, WhitneyCG, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis2005; 192:377 - 86; http://dx.doi.org/10.1086/431521; PMID: 15995950
   PubMed Web of Science ®Google Scholar
• van HoekAJ, AndrewsN, WaightPA, StoweJ, GatesP, GeorgeR, MillerE. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect2012; 65:17 - 24; http://dx.doi.org/10.1016/j.jinf.2012.02.017; PMID: 22394683
   PubMed Web of Science ®Google Scholar
• BridgesCB, Coyne-BeasleyT, Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. MMWR Morb Mortal Wkly Rep2014; 63:110 - 2; PMID: 24500291
   PubMed Web of Science ®Google Scholar
• MaltezouHC, WickerS, BorgM, HeiningerU, PuroV, TheodoridouM, PolandGA. Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine2011; 29:9557 - 62; http://dx.doi.org/10.1016/j.vaccine.2011.09.076; PMID: 21964058
   PubMed Web of Science ®Google Scholar
• EspositoS, MontinaroV, BosisS, TagliabueC, BaggiE, PrincipiN. Recommendations for the use of influenza vaccine in pediatrics. Hum Vaccin Immunother2012; 8:102 - 6; http://dx.doi.org/10.4161/hv.8.1.17957; PMID: 22252005
   PubMed Web of Science ®Google Scholar
• HussA, ScottP, StuckAE, TrotterC, EggerM. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ2009; 180:48 - 58; http://dx.doi.org/10.1503/cmaj.080734; PMID: 19124790
   PubMed Web of Science ®Google Scholar
• MoberleyS, HoldenJ, TathamDP, AndrewsRM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev2013; 1:CD000422; PMID: 23440780
   PubMed Web of Science ®Google Scholar
• MelegaroA, EdmundsWJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol2004; 19:353 - 63; http://dx.doi.org/10.1023/B:EJEP.0000024701.94769.98; PMID: 15180106
   PubMed Web of Science ®Google Scholar
• AndrewsNJ, WaightPA, GeorgeRC, SlackMP, MillerE. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine2012; 30:6802 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.09.019; PMID: 23000122
   PubMed Web of Science ®Google Scholar
• FrenchN, NakiyingiJ, CarpenterLM, LugadaE, WateraC, MoiK, MooreM, AntvelinkD, MulderD, JanoffEN, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet2000; 355:2106 - 11; http://dx.doi.org/10.1016/S0140-6736(00)02377-1; PMID: 10902624
   PubMed Web of Science ®Google Scholar
• ClutterbuckEA, LazarusR, YuLM, BowmanJ, BatemanEA, DiggleL, AngusB, PetoTE, BeverleyPC, MantD, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis2012; 205:1408 - 16; http://dx.doi.org/10.1093/infdis/jis212; PMID: 22457293
   PubMed Web of Science ®Google Scholar
• TörlingJ, HedlundJ, KonradsenHB, OrtqvistA. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine2003; 22:96 - 103; http://dx.doi.org/10.1016/S0264-410X(03)00521-8; PMID: 14604576
   PubMed Web of Science ®Google Scholar
• FedsonDS, Nicolas-SponyL, KlemetsP, van der LindenM, MarquesA, SallerasL, SamsonSI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines2011; 10:1143 - 67; http://dx.doi.org/10.1586/erv.11.99; PMID: 21810065
   PubMed Web of Science ®Google Scholar
• ParadisoPR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis2012; 55:259 - 64; http://dx.doi.org/10.1093/cid/cis359; PMID: 22495545
   PubMed Web of Science ®Google Scholar
• HammittLL, BrudenDL, ButlerJC, BaggettHC, HurlburtDA, ReasonoverA, HennessyTW. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis2006; 193:1487 - 94; http://dx.doi.org/10.1086/503805; PMID: 16652275
   PubMed Web of Science ®Google Scholar
• LexauCA, LynfieldR, DanilaR, PilishviliT, FacklamR, FarleyMM, HarrisonLH, SchaffnerW, ReingoldA, BennettNM, et al, Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA2005; 294:2043 - 51; http://dx.doi.org/10.1001/jama.294.16.2043; PMID: 16249418
   PubMed Web of Science ®Google Scholar
• M. Bonten MB. S. Huijts, C. Webber, S. Gault, W. Gruber, D. Grobbee. Community Acquired Pneumonia Immunisation Trial in Adults (CAPITA). ISPPD. Hyperabad, India, 2014.
   Google Scholar
• SherwinRL, GrayS, AlexanderR, McGovernPC, GraepelJ, PrideMW, PurdyJ, ParadisoP, FileTMJr.. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis2013; 208:1813 - 20; http://dx.doi.org/10.1093/infdis/jit506; PMID: 24092845
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Wunderink RG, Williams D, Zhu Y, Balk R, Fakhran S, Courtney M, Anderson E, Qi C, Hicks L, et al. Distribution of Pneumococcal Serotypes Detected Through Urine Analysis Among US Adults Hospitalized with Pneumonia After Introduction of PCV13. ISPPD. Hyperabad, India, 2014.
   Google Scholar
• WegnerC, HübnerNO, GleichS, ThalmaierU, KrügerCM, KramerA. One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. [8:Doc12]GMS Hyg Infect Control2013; 8:Doc12; PMID: 23967398
   PubMedGoogle Scholar
• KleinEY, LaxminarayanR. The potential impact of age and season on methicillin-resistant Staphylococcus aureus prevalence. Future Microbiol2013; 8:809 - 12; http://dx.doi.org/10.2217/fmb.13.65; PMID: 23841624
   PubMed Web of Science ®Google Scholar
• FogliaG, ShahS, LuxemburgerC, PietrobonPJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine2012; 30:4307 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.01.056; PMID: 22682287
   PubMed Web of Science ®Google Scholar
• JansenKU, GirgentiDQ, ScullyIL, AndersonAS. Vaccine review: “Staphyloccocus aureus vaccines: problems and prospects”. Vaccine2013; 31:2723 - 30; http://dx.doi.org/10.1016/j.vaccine.2013.04.002; PMID: 23624095
   PubMed Web of Science ®Google Scholar
• DonaldRG, FlintM, KalyanN, JohnsonE, WitkoSE, KotashC, ZhaoP, MegatiS, YurgelonisI, LeePK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology2013; 159:1254 - 66; http://dx.doi.org/10.1099/mic.0.066712-0; PMID: 23629868
   PubMed Web of Science ®Google Scholar
• LowyFD. Staphylococcus aureus infections. N Engl J Med1998; 339:520 - 32; http://dx.doi.org/10.1056/NEJM199808203390806; PMID: 9709046
   PubMed Web of Science ®Google Scholar
• KleinE, SmithDL, LaxminarayanR. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis2009; 15:1925 - 30; http://dx.doi.org/10.3201/eid1512.081341; PMID: 19961671
   PubMed Web of Science ®Google Scholar
• KleinE, SmithDL, LaxminarayanR. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis2007; 13:1840 - 6; http://dx.doi.org/10.3201/eid1312.070629; PMID: 18258033
   PubMed Web of Science ®Google Scholar
• SimorAE, BradleySF, StrausbaughLJ, CrossleyK, NicolleLE. Committee SL-T-C. Clostridium difficile in long-term-care facilities for the elderly. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America2002; 23:696 - 703; http://dx.doi.org/10.1086/501997
   PubMed Web of Science ®Google Scholar
• RupnikM, WilcoxMH, GerdingDN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol2009; 7:526 - 36; http://dx.doi.org/10.1038/nrmicro2164; PMID: 19528959
   PubMed Web of Science ®Google Scholar
• SeekatzAM, YoungVB. Clostridium difficile and the microbiota. J Clin Invest2014; 1 - 8; PMID: 25036699
   PubMed Web of Science ®Google Scholar
• GouldIM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents2006; 28:379 - 84; http://dx.doi.org/10.1016/j.ijantimicag.2006.09.001; PMID: 17045462
   PubMed Web of Science ®Google Scholar
• DubberkeE. Clostridium difficile infection: the scope of the problem. J Hosp Med2012; 7:Suppl 3S1 - 4; http://dx.doi.org/10.1002/jhm.1916; PMID: 22407993
   PubMedGoogle Scholar
• CosgroveSE, QiY, KayeKS, HarbarthS, KarchmerAW, CarmeliY. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol2005; 26:166 - 74; http://dx.doi.org/10.1086/502522; PMID: 15756888
   PubMed Web of Science ®Google Scholar
• ChengAG, DeDentAC, SchneewindO, MissiakasD. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol2011; 19:225 - 32; http://dx.doi.org/10.1016/j.tim.2011.01.007; PMID: 21353779
   PubMed Web of Science ®Google Scholar
• AndersonAS, MillerAA, DonaldRG, ScullyIL, NanraJS, CooperD, JansenKU. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother2012; 8:1585 - 94; http://dx.doi.org/10.4161/hv.21872; PMID: 22922765
   PubMed Web of Science ®Google Scholar
• BroughanJ, AndersonR, AndersonAS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccines2011; 10:695 - 708; http://dx.doi.org/10.1586/erv.11.54; PMID: 21604989
   PubMed Web of Science ®Google Scholar
• FowlerVG, AllenKB, MoreiraED, MoustafaM, IsgroF, BoucherHW, CoreyGR, CarmeliY, BettsR, HartzelJS, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA2013; 309:1368 - 78; http://dx.doi.org/10.1001/jama.2013.3010; PMID: 23549582
   PubMed Web of Science ®Google Scholar
• ShinefieldH, BlackS, FattomA, HorwithG, RasgonS, OrdonezJ, YeohH, LawD, RobbinsJB, SchneersonR, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med2002; 346:491 - 6; http://dx.doi.org/10.1056/NEJMoa011297; PMID: 11844850
   PubMed Web of Science ®Google Scholar
• BradyRA, O’MayGA, LeidJG, PriorML, CostertonJW, ShirtliffME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun2011; 79:1797 - 803; http://dx.doi.org/10.1128/IAI.00451-10; PMID: 21220484
   PubMed Web of Science ®Google Scholar
• LattarSM, Noto LlanaM, DenoëlP, GermainS, BuzzolaFR, LeeJC, SordelliDO. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun2014; 82:83 - 91; http://dx.doi.org/10.1128/IAI.01050-13; PMID: 24126523
   PubMed Web of Science ®Google Scholar
• Stranger-JonesYK, BaeT, SchneewindO. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A2006; 103:16942 - 7; http://dx.doi.org/10.1073/pnas.0606863103; PMID: 17075065
   PubMed Web of Science ®Google Scholar
• NanraJS, BuitragoSM, CrawfordS, NgJ, FinkPS, HawkinsJ, ScullyIL, McNeilLK, Aste-AmézagaJM, CooperD, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother2013; 9:480 - 7; http://dx.doi.org/10.4161/hv.23223; PMID: 23249887
   PubMed Web of Science ®Google Scholar
• HawkinsJ, KodaliS, MatsukaYV, McNeilLK, MininniT, ScullyIL, VernachioJH, SeverinaE, GirgentiD, JansenKU, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol2012; 19:1641 - 50; http://dx.doi.org/10.1128/CVI.00354-12; PMID: 22896688
   PubMed Web of Science ®Google Scholar
• HandkeLD, RogersKL, OlsonME, SomervilleGA, JerrellsTJ, RuppME, DunmanPM, FeyPD. Staphylococcus epidermidis saeR is an effector of anaerobic growth and a mediator of acute inflammation. Infect Immun2008; 76:141 - 52; http://dx.doi.org/10.1128/IAI.00556-07; PMID: 17954724
   PubMed Web of Science ®Google Scholar
• MishraRP, MariottiP, FiaschiL, NosariS, MaccariS, LiberatoriS, FontanaMR, PezzicoliA, De FalcoMG, FalugiF, et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis2012; 206:1041 - 9; http://dx.doi.org/10.1093/infdis/jis463; PMID: 22829645
   PubMed Web of Science ®Google Scholar
• KoreaCG, BalsamoG, PezzicoliA, MerakouC, TavariniS, BagnoliF, SerrutoD, UnnikrishnanM. The staphylococcal Esx proteins modulate apoptosis and release of intracellular Staphylococcus aureus during infection in epithelial cells. Infect Immun2014; http://dx.doi.org/10.1128/IAI.01576-14; PMID: 25047846
   PubMed Web of Science ®Google Scholar
• BecherelliM, PrachiP, VicianiE, BiaginiM, FiaschiL, ChiarotE, NosariS, BrettoniC, MarchiS, BiancucciM, et al. Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins. PLoS One2013; 8:e74718; http://dx.doi.org/10.1371/journal.pone.0074718; PMID: 24069334
   PubMed Web of Science ®Google Scholar
• KuehneSA, CartmanST, HeapJT, KellyML, CockayneA, MintonNP. The role of toxin A and toxin B in Clostridium difficile infection. Nature2010; 467:711 - 3; http://dx.doi.org/10.1038/nature09397; PMID: 20844489
   PubMed Web of Science ®Google Scholar
• LeuzziR, AdamoR, ScarselliM. Vaccines against Clostridium difficile. Hum Vaccin Immunother2014; 10:1 - 12; http://dx.doi.org/10.4161/hv.28428; PMID: 24832715
   PubMed Web of Science ®Google Scholar
• KotloffKL, WassermanSS, LosonskyGA, ThomasWJr., NicholsR, EdelmanR, BridwellM, MonathTP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun2001; 69:988 - 95; http://dx.doi.org/10.1128/IAI.69.2.988-995.2001; PMID: 11159994
   PubMed Web of Science ®Google Scholar
• GreenbergRN, MarburyTC, FogliaG, WarnyM. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine2012; 30:2245 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.01.065; PMID: 22306375
   PubMed Web of Science ®Google Scholar
• Valneva. . An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84, NCT01296386ClinicalTrialsgov. , 2014
   Google Scholar
• Pfizer. Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years, NCT01706367. ClinicalTrialsgov. 2014;
   Google Scholar
• BlankPR, SchwenkglenksM, SzucsTD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect2009; 58:446 - 58; http://dx.doi.org/10.1016/j.jinf.2009.04.001; PMID: 19446340
   PubMed Web of Science ®Google Scholar
• FioreAE, UyekiTM, BroderK, FinelliL, EulerGL, SingletonJA, IskanderJK, WortleyPM, ShayDK, BreseeJS, et al, Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep2010; 59:RR-81 - 62; PMID: 20689501
   PubMedGoogle Scholar
• WilliamsWW, LuPJ, O’HalloranA, BridgesCB, PilishviliT, HalesCM, MarkowitzLE, Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults - United States, 2012. MMWR Morb Mortal Wkly Rep2014; 63:95 - 102; PMID: 24500288
   PubMed Web of Science ®Google Scholar
• OxmanMN, LevinMJ, JohnsonGR, SchmaderKE, StrausSE, GelbLD, ArbeitRD, SimberkoffMS, GershonAA, DavisLE, et al, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
   PubMed Web of Science ®Google Scholar
• SchmaderKE, OxmanMN, LevinMJ, JohnsonG, ZhangJH, BettsR, MorrisonVA, GelbL, GuatelliJC, HarbeckeR, et al, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis2012; 55:1320 - 8; http://dx.doi.org/10.1093/cid/cis638; PMID: 22828595
   PubMed Web of Science ®Google Scholar
• KanitzEE, WuLA, GiambiC, StrikasRA, Levy-BruhlD, StefanoffP, MereckieneJ, AppelgrenE, D’AnconaF, VENICE (Vaccine European New Integrated Collaboration Effort) National Gatekeepers, Contact Points. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine2012; 30:5222 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.06.012; PMID: 22721901
   PubMed Web of Science ®Google Scholar
• Boutriau D. Evaluation of an investigational 4-componant Staphylococcus aureus vaccine with or without AS03B adjuvant in healthy adults: results from a phase 1 trial. International Symposium on Staphylococci and Staphylococcal Infections, Chicago, USA August 26-29 1014
   Google Scholar